Machine Learning for Improved Clinical Outcomes
Precision as a Service™
At PlenaryAI, we help physicians see the bigger picture. Our aim is to provide clinical staff with customized artificial intelligence tools to help them make more informed decisions for patients. We combine relevant biomarkers and multi-modality imaging in order to put each patient's unique information against the backdrop of a vast amount of data analytics. Led by world-class experts from leading biomedical research systems, including Johns Hopkins University and the University of Maryland Medical Center, PlenaryAI has access to the latest technology, clinical services, data and medical thinking to revolutionize precision health.
PRODUCT PL01
Automated Screening, Diagnostic, and Prognostic Assessment
Our Artificial Intelligence (AI) and Deep Learning (DL) solutions help medical imaging professionals interpret the ever-growing number of images they analyze in their research and clinical practices. PlenaryAI has developed a real-time, AI-assisted quantitative assessment tool for molecular images that can objectively and automatically identify, segment, and classify tissue types. Our technology provides real-time, biochemical information to clinicians for detection, diagnosis and assessing response to therapy. In addition to its contribution to the clinical domain, this tool is equally valuable in pre-clinical studies to promote translation of promising new technology to clinical use.
PRODUCT PL02
Machine Learning for Cancer Classification on PET
Positron Emission Tomography (PET) images are typically evaluated by radiologists for detection and monitoring of malignant conditions, but this manual process is often time-consuming, expensive, and subject to reader variability. Our machine learning framework automates this image analysis, characterizing malignant lesions on PET images systematically. Our technology has been focused on classifying prostate cancer lesions using an imaging agent that targets the prostate-specific membrane antigen (PSMA). But it can assist in the diagnosis and prognosis of other cancers, as well as PET-based radiation therapy treatment planning.
PRODUCT PL03
Machine Learning for Parkinson’s Disease Subtype Selection
We are unraveling the mysteries of heterogeneous outcomes. Physicians have traditionally relied on observation and communication among themselves to discover new diseases or variants of disorders that affect patient treatments and outcomes. In the case of Parkinson’s disease, we can use machine learning to subtype patients into subgroups who differ with respect to symptoms and signs, which may include deficits related to cognition, motor skills or decreased sense of smell. Such subtyping will enable physicians to educate patients and their families about their prognosis, and enable more appropriate, tailored, treatment. PlenaryAI’s advanced machine learning methods automate and scale this process, combining vast, complex data sets to optimally characterize each patient, indicate divergent outcomes, and discover alternative treatments.
